Press Releases
Myasthenia Gravis Market to Become Worth US$ 2,313.1 Million by 2025

Myasthenia Gravis Market

, 14 February 2018 -- Myasthenia Gravis Market (Treatment- Drug Treatment (Cholinesterase Inhibitors, Monoclonal Antibodies, and Chronic Immunomodulators) and Rapid Immunotherapies (Plasmapheresis, Intravenous Immunoglobulin (IVlg), and Thymectomy)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025.

According to a research report by Transparency Market Research (TMR), the global myasthenia gravis market is anticipated to be worth US$2,313.1 mn by the end of 2025 from a valuation of US$975.1 mn in 2016. During the forecast period of 2017 and 2025, the global myasthenia gravis market is projected to clock a CAGR of 10.1%. The key treatment segments include cholinesterase inhibitors, monoclonal antibodies, and chronic Immunomodulators. Among the key regional segments, North America has emerged as a key market for myasthenia gravis on account of a considerable prevalence of myasthenia gravis in the U.S.

Report Overview @

The rising prevalence of myasthenia gravis that can impact life quality is primarily driving the myasthenia gravis market. Myasthenia gravis is an autoimmune disorder and neuromuscular disorder that causes muscle weakness. The condition is characterized by fatigability and weakness of skeletal muscles, wherein development follows respite. Muscles which are usually impacted are the ones that monitor swallowing and breathing, eye movement, eye lids, and shoulder and facial muscles. The condition affects muscles that a person can control consciously. The weakness of muscles worsens with movement and improves with rest.

In myasthenia gravis, the muscle cells have difficulties to contract and respond to nerve impulses which results in weakness of muscles.

Request for Sample Copy of Report @

Myasthenia gravis is initiated due to a decline in the number of postsynaptic acetylcholine receptors at neuromuscular joints. This results in reduction of size of neuromuscular end-plate to communicate the nerve signal. In a normal state, acetylcholine is released presynaptically in response to a stimulus resultant in depolarization that results in muscle action. On the other hand, in myasthenia gravis, the number of active postsynaptic receptors may be inadequate to trigger a potential of muscle action. Further, with repeated stimulus, the decline in release of acetylcholine correlates with fatigability.

Nevertheless, myasthenia gravis usually does not impact life expectancy. Patients of myasthenia gravis manage their symptoms and lead active lives. The condition is prevalent among people of all ages and ethnicities. Typically, myasthenia gravis is prevalent among men of middle age and among women between 20 to 30 years of age.

Request a Brochure of the Report @

Research and development for therapeutics for myasthenia gravis is stoking growth of myasthenia gravis market. Symptomatic and casual treatments are the key therapeutics for myasthenia gravis. The symptomatic treatment involves increasing the duration of presence of acetylcholine, which is responsible for transmitting the nerve impulse by antagonizing acetylcholinesterase.

Despite a largely consolidated vendor landscape with several large players and a few regional players, competition in the global myasthenia gravis market is stiff. In this scenario, key players hold small market shares. Alexion Pharmaceutical Inc., Avadel Pharmaceuticals plc, CSL Behring, Grifols S.A., Baxter International Inc., Shire plc, Novartis AG, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, and Valeant Pharmaceuticals International Inc. are to name some prominent companies in the global myasthenia gravis market. These companies are focused on research and development for novel therapeutics for myasthenia gravis. This is one of the key strategic moves adopted by companies operating in the myasthenia gravis market. Further, clinical trials to introduce affordable therapeutics is also an important growth strategy of these companies.

Enquiry for discount on this report @

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

# # #

Submitted by hawer on Wednesday, 14 February 2018 at 4:43 PM
Category: Health Care & Medical
Related News

Immunoassay Instruments Market to Reach US$23.3 bn by 2020
Monday, 21 May 2018

Continuous Glucose Monitoring Market to Grow at a CAGR of 13.60% through 2019
Monday, 21 May 2018

Medical Fiber Optics Market CAGR Projected to Grow at 7.60% through 2019
Monday, 21 May 2018

Surgical Navigation Systems Market to Reach US$295.5 Mn by 2020
Monday, 21 May 2018

Cell Culture Protein Surface Coatings Market will Exhibit a Steady 13.60% CAGR through 2020
Monday, 21 May 2018

Related Events

2018 Off-Label Regulatory Compliance Congress
Monday, 21 May 2018

4th European Clinical Trials Inspection Readiness
Monday, 21 May 2018

Medicaid Managed Care Congress
Monday, 21 May 2018

Drug Delivery Design & Partnering - May 21-22, 2018 - San Francisco, CA
Monday, 21 May 2018

Product Recalls Forum
Monday, 21 May 2018

Latest News

The ‘Shen Yun’ show provokes controversy
Tuesday, 22 May 2018

Mostofi Yachts Unveils New Yacht
Tuesday, 22 May 2018

How to select the Best crypto exchange service?
Monday, 21 May 2018

What are the benefits of using iCoin?
Monday, 21 May 2018

Ready to Assemble Furniture Market Outlook: Ken Research
Monday, 21 May 2018

Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2018
Today is Tuesday, 22 May 2018

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Consumer Technology
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
News & Media
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!

Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.

  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.

  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • Argus Latin America LNG Summit
  • Argus North American Natural Gas Markets
  • Drug Delivery Design & Partnering - May 21-22, 2018 - San Francisco, CA
  • 4th European Clinical Trials Inspection Readiness
  • 2018 Off-Label Regulatory Compliance Congress

  • Latest Jobs
    Sorry, there are currently no entries posted here.